Insider transaction details
Rebecca Taub, who serves on the board of Madrigal Pharmaceuticals (NASDAQ: MDGL), had 647 shares of common stock sold on January 26, 2026, at a price of $492.42 per share. The sale produced a total proceeds figure of $318,595.
Following the sale, Taub directly holds 452,704 shares of Madrigal stock. In addition to her direct holdings, she has an indirect interest of 655,540 shares through SQN LLC.
The disposition was executed by Madrigal on Taub's behalf to satisfy tax-withholding obligations that arose from the vesting of restricted stock units. The company characterized the sale as automatic and not undertaken at Taub's discretion.
Company developments and commercial performance
Madrigal has disclosed several operational milestones that have attracted investor attention. The company reported that its drug Rezdiffra reached more than $1 billion in annualized sales as of the third quarter of 2025. The company also disclosed patient and prescriber engagement metrics, noting that Rezdiffra now reaches 29,500 patients and has been prescribed by over 10,000 prescribers.
Separately, Madrigal entered into an exclusive global license agreement with Pfizer for ervogastat, a clinical-stage DGAT-2 inhibitor aimed at expanding the company’s pipeline for treating metabolic-associated steatohepatitis (MASH).
Analyst reactions
Market analysts have responded to the licensing deal and the commercial update with differing assessments.
- Truist Securities reaffirmed a Buy rating and maintained a price target of $640.00, viewing the Pfizer license as a potential strengthener for Madrigal’s MASH treatment pipeline.
- Citizens increased its price target to $745.00 and kept a Market Outperform rating, while noting that Madrigal shares had fallen about 14% since early 2026.
- Goldman Sachs reiterated a Buy rating with a price target of $571.00 following Madrigal’s presentation at an investor conference.
- Wolfe Research downgraded Madrigal from Outperform to Peerperform, citing concerns over a high valuation and the patent strength of competitor Inventiva, and set a fair value of $572 per share.
Context and current outlook
These disclosures and analyst reactions together illustrate a period of active corporate developments for Madrigal, combining strong commercial performance metrics for Rezdiffra with strategic pipeline expansion via the Pfizer license. Analysts remain split in their assessments, providing a range of price targets and ratings based on differing views of valuation and competitive risks.
Because the insider sale was an automatic tax-withholding event tied to restricted stock unit vesting, it should be interpreted as a non-discretionary transaction rather than a voluntary divestiture by the director.